The risk that a clinical-stage company with no marketing-authorized products will be unable to obtain marketing approval for its product candidates, resulting in significant losses affecting commercialization and business continuity. This covers the company’s status as having no approved products and the impact of failing to obtain approval, rather than delays involving a specific development product.